{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:32:57Z","timestamp":1789237977173,"version":"build-2803163510"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ejca.2021.01.012","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T05:56:56Z","timestamp":1613368616000},"page":"84-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Immunotherapy-refractory, EGFR overexpressing metastatic porocarcinoma responding to cetuximab"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8591-0788","authenticated-orcid":false,"given":"Francesca","family":"Comito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Nigro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sperandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Melotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2678-0714","authenticated-orcid":false,"given":"Andrea","family":"Ardizzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejca.2021.01.012_bib1","doi-asserted-by":"crossref","DOI":"10.1111\/ijd.12714","article-title":"Eccrine porocarcinoma: epidemiologic and histopathologic characteristics","volume":"54","author":"Riera-Leal","year":"2015","journal-title":"Int J Dermatol"},{"issue":"9","key":"10.1016\/j.ejca.2021.01.012_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/ijd.12448","article-title":"Poroma: a review of eccrine, apocrine, and malignant forms","volume":"53","author":"Sawaya","year":"2014","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.ejca.2021.01.012_bib3","article-title":"Primary apocrine adenocarcinoma of the axilla","volume":"95","author":"Kathrotiya","year":"2015","journal-title":"Cutis"},{"key":"10.1016\/j.ejca.2021.01.012_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijscr.2016.10.051","article-title":"Porocarcinoma: a systematic review of literature with a single case report","volume":"30","author":"Salih","year":"2017","journal-title":"Int J Surg Case Rep"},{"issue":"9","key":"10.1016\/j.ejca.2021.01.012_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-228917","article-title":"Metastatic porocarcinoma achieving complete radiological and clinical response with pembrolizumab","volume":"12","author":"Lee","year":"2019","journal-title":"BMJ Case Rep"},{"issue":"10","key":"10.1016\/j.ejca.2021.01.012_bib6","article-title":"Chemotherapy of rare skin adnexal tumors: a review of literature","volume":"34","author":"De Iuliis","year":"2014","journal-title":"Anticancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2021.01.012_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/modpathol.2011.48","article-title":"A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas","volume":"24","author":"Dias-Santagata","year":"2011","journal-title":"Mod Pathol"},{"issue":"10","key":"10.1016\/j.ejca.2021.01.012_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047290","article-title":"Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses","volume":"7","author":"Le","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2021.01.012_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2015.12.015","article-title":"Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations","volume":"51","author":"Harms","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ejca.2021.01.012_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2017.11.009","article-title":"Complete response of a metastatic porocarcinoma treated with paclitaxel, cetuximab and radiotherapy","volume":"90","author":"Godillot","year":"2018","journal-title":"Eur J Canc"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492100023X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492100023X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:30:05Z","timestamp":1760733005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492100023X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":10,"alternative-id":["S095980492100023X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.01.012","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy-refractory, EGFR overexpressing metastatic porocarcinoma responding to cetuximab","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}